Myriad Genetics financials
$4.23−0.24%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $190.7M | $200.4M | $209.8M | $205.7M | $213.1M | $195.9M | $210.6M | $213.3M | $211.5M | $202.2M | $196.6M | $191.9M |
| Gross profit | $127.0M | $137.6M | $146.8M | $143.8M | $151.8M | $134.2M | $150.9M | $149.8M | $147.1M | $137.6M | $135.0M | $134.3M |
| Gross margin | 66.6% | 68.7% | 70.0% | 69.9% | 71.2% | 68.5% | 71.7% | 70.2% | 69.6% | 68.1% | 68.7% | 70.0% |
| Operating income | -$38.9M | -$30.7M | -$5.7M | -$23.3M | -$329.2M | -$29.0M | -$39.0M | -$20.0M | -$36.5M | -$27.9M | -$31.4M | -$60.1M |
| Net income | -$43.2M | -$34.1M | -$7.9M | -$27.4M | -$330.5M | -$100.0K | -$42.5M | -$22.1M | -$36.7M | -$26.0M | -$31.2M | -$61.3M |
| Net margin | −22.7% | −17.0% | −3.8% | −13.3% | −155.1% | −0.1% | −20.2% | −10.4% | −17.4% | −12.9% | −15.9% | −31.9% |
| Diluted EPS | $-0.46 | $-0.36 | $-0.08 | $-0.29 | $-3.57 | $0.00 | $-0.47 | $-0.24 | $-0.41 | $-0.29 | $-0.36 | $-0.75 |
| EBITDA | -$26.4M | -$12.8M | $9.6M | -$10.7M | $1.6M | -$14.6M | $18.8M | -$2.2M | -$9.8M | -$12.2M | $81.4M | -$46.0M |
| Operating cash flow | -$8.3M | -$15.7M | $10.6M | $21.1M | -$13.6M | -$16.3M | $6.6M | $700.0K | $2.6M | -$18.6M | -$54.7M | -$22.1M |
| Free cash flow | -$10.4M | -$21.1M | $5.9M | $18.3M | -$16.4M | -$21.6M | $3.0M | -$2.8M | -$2.6M | -$25.3M | -$68.2M | -$39.6M |
| Diluted shares | 94.8M | 93.7M | 93.4M | 93.1M | 92.5M | 91.4M | 91.0M | 90.9M | 90.6M | 89.9M | 86.3M | 81.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $115.2M | $124.4M | $149.6M | $145.4M | $74.4M | $91.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $120.7M | $120.3M | $119.9M | $119.5M | $59.4M | $59.3M |
| Total assets | $638.9M | $673.7M | $706.6M | $728.1M | $677.3M | $1.01B |
| Total liabilities | $335.0M | $336.3M | $338.6M | $355.3M | $289.2M | $301.2M |
| Shareholders' equity | $303.9M | $337.4M | $368.0M | $372.8M | $388.1M | $704.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology